Non–Small Cell Lung Cancer Coverage from Every Angle

Karen L. Reckamp, MD, on Ramucirumab Plus Pembrolizumab for NSCLC: Practical Clinical Considerations

Posted: Friday, July 8, 2022

Karen L. Reckamp, MD, of Cedars-Sinai Medical Center, discusses findings from the Lung-MAP protocol, which showed that ramucirumab and pembrolizumab improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) who were previously treated with immunotherapy and platinum-based chemotherapy. Among the topics Dr. Reckamp focuses on are the discordance between overall response rate and progression-free survival results vs overall survival; PD-L1 status; and toxicity.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.